Trials / Terminated
TerminatedNCT02534896
To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (actual)
- Sponsor
- Sun Pharmaceutical Industries Limited · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This study is designated to evaluate the safety and efficacy of Sunpharma1505 in subjects with active rheumatoid arthritis who are experiencing a flare/exacerbation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Treatment I | Sunpharma1505 and Placebo |
| DRUG | Treatment II | Sunpharma1505 and Placebo |
| DRUG | Treatment III | Reference1505 and Placebo |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2018-03-01
- Completion
- 2018-06-01
- First posted
- 2015-08-28
- Last updated
- 2021-11-19
- Results posted
- 2019-11-21
Locations
20 sites across 2 countries: Belgium, Netherlands
Source: ClinicalTrials.gov record NCT02534896. Inclusion in this directory is not an endorsement.